SUPPORT FOR THE PRECLINICAL DEVELOPMENT OF EIF4A INHIBITORS ROCAGLAMIDE AND DIDESMETHYLROCAGLAMIDE. (TOXICIOLOGY SERVICES TO SUPPORT PRECLINICAL DRUG
$588,615N01FY2020CANIH
Iit Research Institute, Chicago IL
Investigators
Abstract
Support for the Preclinical Development of eIF4A inhibitors Rocaglamide and Didesmethylrocaglamide
View original record on NIH RePORTER →